Similarly, in the dose-expansion phase of the multicenter CheckMate 040 trial, which investigated the PD-1 inhibitor nivolumab in patients with advanced HCC, CPS at 1% was not associated with having an objective response [96]. Here, PDCD1 is linked to hepatocellular carcinoma.